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bstract
Ultracentrifugation in sucrose density gradient remains the most commonly used technique for hRSV purification. However, the high viscosity
nd hyper-osmotic property of sucrose can cause damage to the extremely labile virus leading to loss of infectivity. To overcome these limitations,
n alternative purification technique was developed using iodixanol as gradient medium, incorporating MgSO4 as a stabilizing agent and EDTA
o disaggregate the virus prior to infectivity assay. Virus particles were banded at the 20–36% interface after purification of polyethylene glycol-
oncentrated viruses by rate zonal ultracentrifugation on a 20–52% discontinuous iodixanol gradient. The presence of the virus was confirmed by
iral fusion glycoprotein content using ELISA. After further purification by buoyant density ultracentrifugation on a 20–52% continuous gradient,
he virus was recovered in the region of density 1.15–1.19 g/ml and this was confirmed by the coincidence of the infectivity titre, viral genome
nd fusion glycoprotein peaks. Analysis of recovery rates showed that the use of iodixanol increased the virus yield up to 69%. Iodixanol was also
ound to be non-toxic to HeLa cells used in infectivity assay, eliminating the need of its downstream removal by dialysis.
2007 Elsevier B.V.
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. Introduction
Human respiratory syncytial virus (hRSV) is an enveloped,
ingle stranded, negative sense RNA virus belonging to the genus
neumovirus and familyParamyxoviridae (Fauquet et al., 2005).
t is a medically important paediatric virus responsible for acute
espiratory illnesses worldwide (Weber et al., 1998). The virus
article is composed of a helical nucleocapsid enclosed by a
ipid envelope studded with three transmembrane glycoproteins,
, F and SH (Collins et al., 2001). While the function of SH
rotein is yet unknown, the G and F glycoproteins mediate virus
ttachment and fusion, respectively, and are major targets of the
rotective host immune response (Elango et al., 1986; Routledge
t al., 1988; Walsh et al., 1998).
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Purified hRSV preparations are often required for characteri-
ation and immunological studies. Multiple steps of differential
nd density gradient ultracentrifugation have commonly been
sed to purify hRSV, a procedure which takes many hours and
an result in considerable loss of infectivity for this fragile
irus. The recovery rates have been improved by the addition
f MgSO4 to the buffer during purification (Fernie and Gerin,
980) and Ueba (1978) reported that sucrose in concentrations
bove 15% also has a stabilizing effect. Mbiguino and Menezes
1991) found that fractionation on sucrose gradients gave better
irus recovery than percoll, renografin and metrizamide gra-
ients. However, ultracentrifugation in sucrose is damaging to
irus particles (Trepanier et al., 1981) and yields remain variable
nd often unsatisfactory. For example, although Mbiguino and
enezes (1991) report recovery of 57%, Ueba (1978) recovered
9% and Trepanier et al. (1981) 22% of virus after centrifugation
hrough two successive sucrose density gradients. In addition to
oor recovery of infectivity, sucrose is also toxic to cells used to
row the virus and this affects downstream experimental work
hich requires the use of cell cultures such as viral infectivity
ssays.
gical
p
n
p
M
h
e
s
t
r
b
T
t
t
a
i
A
u
a
2
2
f
a
a
i
A
2
a
E
f
1
b
w
o
w
l
t
g
f
a
2
5
fl
c
s
4
p
r
b
a
m
a
i
i
i
b
T
I
m
2
i
P
M
m
g
i
2
o
v
d
m
b
v
c
b
i
g
s
J
s
w
P
t
1
2
b
s
T
s
A
m
NE. Gias et al. / Journal of Virolo
Iodixanol (OptiPrepTM) has been used successfully in the
urification of various viruses such as HIV-1, HTLV-1, recombi-
ant adeno-associated virus (rAAV), MoMLV-derived retrovirus
articles (Dettenhofer and Yu, 1999; Hermens et al., 1999;
oller-Larsen and Christensen, 1998; Segura et al., 2006) and
epatitis C virus (Nielsen et al., 2006). Iodixanol offers sev-
ral advantages over sucrose. The medium is less viscous than
ucrose and non-toxic to cells, allowing subsequent viral infec-
ivity assays to be carried out directly without the need for
emoval. Iodixanol also has a low osmolarity and therefore can
e diluted in iso-osmotic buffers to form iso-osmotic solutions.
his allows the virus to be purified under iso-osmotic condi-
ions and thus better preserve the integrity and functionality of
he virus particles (Axis-Shield, 2004).
In the present study, the use of iodixanol was investigated
s a medium for purifying hRSV in an attempt to obtain an
mproved recovery rate of intact and infectious virion particles.
purification procedure was developed based on the method of
ltracentrifugation in sucrose gradients described by Mbiguino
nd Menezes (1991).
. Materials and methods
.1. Virus
hRSV strains R17532 (1994) and N5843 (1990) were isolated
rom infected infants in Newcastle upon Tyne and passaged three
nd one times, respectively, in HeLa cells. Stocks were prepared
s described in Section 2.2 after two rounds of biological cloning
n Vero cells. The hRSV strain A2 was kindly supplied by Dr
.J. Stott, Institute of Animal Health, Compton, UK.
.2. Cell culture
Human cervical carcinoma (HeLa) cells were cultured in
225 cm2 cell culture flask (Corning Incorporated, USA) in
agle’s minimal essential medium supplemented with 10%
oetal calf serum (FCS), 10 mg/ml of penicillin-streptomycin,
% of 200 mM L-glutamine and 5% gassed sodium bicar-
onate containing 0.4% phenol red. The virus-infected cells
ere maintained in Medium 199 Earles Salts containing 2%
f FCS.
Confluent HeLa cell cultures infected with each virus strain
ere harvested when cytopathic effect involved the whole mono-
ayer, snap-frozen in liquid nitrogen and stored at −80 ◦C. On
hawing, the infected cell suspensions were clarified by centrifu-
ation in a JLA 10.5 rotor (Beckman Coulter, USA) at 3250 × g
or 20 min at 4 ◦C. The clarified viral supernatants were then
djusted to 100 mM MgSO4 and 50 mM Tris–HCl (pH 7.5).
.3. Virus concentration
Fifty percent (w/v) PEG 6000 in NT buffer (150 mM NaCl,
0 mM Tris–HCl, pH 7.5) was added to the clarified culture
uid to a final concentration of 10% (v/v). The virus parti-
les were then precipitated for 90 min at 4 ◦C with moderate
tirring, followed by centrifugation at 3250 × g for 20 min at
w
D
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◦C in a JLA 10.5 rotor. After removing the supernatant, the
ellet was re-centrifuged as above and the residual fluids were
emoved. The pellet was then re-suspended in 1 ml of cold NT
uffer. A sample was taken out and EDTA was incorporated to
final concentration of 1 mM and the infectivity titre was deter-
ined by the infectious focus assay in HeLa cell monolayers
s described by Routledge et al. (1988). Eighteen hours after
nfection the infected monolayers were fixed with 75% acetone
n phosphate buffered saline. Infectious foci were visualised by
ndirect immunofluorescence with a pool of monoclonal anti-
odies to hRSV (Novocastra Laboratories Ltd., Newcastle upon
yne, UK) followed by fluorescein conjugated goat anti-mouse
gG (Dako UK Ltd., Ely, UK) and counted under a fluorescence
icroscope.
.4. Puriﬁcation by ultracentrifugation
Discontinuous gradients were prepared by sequentially layer-
ng 52, 36 and 20% iodixanol solution (OptiPrepTM, Axis-Shield
oC AS, Oslo, Norway) in 10 mM Tris–HCl, pH 7.5, 100 mM
gSO4 and 0.25 M sucrose into 14 ml centrifuge tubes (Beck-
an Coulter UK Ltd., High Whickham, Bucks, UK), and the
radients were used immediately. Continuous gradients contain-
ng iodixanol solution to final concentrations of 52, 42, 32 and
0% were prepared in the same manner but left in the dark at 4 ◦C
vernight to allow the gradient to diffuse. PEG-concentrated
irus samples were adjusted to 100 mM MgSO4, layered over a
iscontinuous gradient and centrifuged in a SW-40 rotor (Beck-
an Coulter) for 90 min at 35,000 rpm at 4 ◦C. An opaque virus
and was visible at the 20–30% interface. Fractions were har-
ested and the opaque band was recovered and diluted 1:2 in
old NT buffer containing 100 mM MgSO4. The diluted virus
and was layered over the continuous gradient and centrifuged
n a SW-40 rotor for 18 h at 35,000 rpm at 4 ◦C. After 18 h,
radient fractions were harvested and the densities of fraction
amples were measured using a refractometer (ATAGO, Tokyo,
apan) after which they were snap-frozen in liquid nitrogen and
tored at −80 ◦C. The presence of hRSV in fraction samples
as determined by MAb-capture ELISA and quantitative RT-
CR (see below), and the infectivity titres were determined by
he infectious focus assay as described above in the presence of
mM EDTA.
.5. Monoclonal antibody (MAb)-capture ELISA
The hRSV F glycoprotein in gradient fractions was detected
y MAb-capture ELISA as described by Morgan (1988). Virus
amples were serially diluted 2-fold in PBS containing 0.05%
ween 20 and 10% foetal calf serum. 50l per well of
amples and control antigens (non-infected and hRSV strain
2 infected HeLa cells) followed by 20l of antigen treat-
ent buffer (20 mM of NaC1, 0.72 mM of KH2PO4, 4 mM
a2HPO4·12H2O and 1.3 mM of KCl) were added to the 96-
ell Maxisorp Nunc-Immunoplate plates (NuncTM, Roskilde,
enmark) coated with 1 in 400 dilution of anti-F MAb IE3
scites and incubated at 37 ◦C for 2 h. The presence of hRSV
ntigen was detected by a 1 in 600 dilution of a polyclonal
3 gical Methods 147 (2008) 328–332
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Fig. 1. Purification of PEG-concentrated hRSV strain R17532 on discontinuous
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abbit anti-hRSV serum for 1 h followed by 1 in 1000 dilution
f peroxidase-conjugated swine immunoglobulins to rabbit IgG
Dako) for another hour. 100l per well of freshly prepared com-
lete substrate solution containing 62.5 mg/ml of OPD, 0.02 M
f citric acid, 0.06 M of Na2HPO4 and 0.01% H2O2 was added,
ncubated at 37 ◦C for 30 min and the colour development was
topped by the addition of 100l per well of 3M H2SO4. The
ptical density of each well was then measured using an MRX
late reader at an absorbance of 492 nm. To test the specificity
f the assay, the rabbit polyclonal anti-hRSV antibody/anti-
abbit peroxidise detector system was replaced with monoclonal
ntibodies to the hRSV F, G and N proteins and peroxidase
abelled anti-mouse immunoglobulins (Abcam Plc, Cambridge,
K). While anti-F MAb bound well in this system, the bind-
ng of MAbs to other viral proteins was negligible (data not
hown).
.6. Quantitative reverse transcriptase polymerase chain
eaction (RT-PCR) for hRSV genome
The amount of hRSV genome in fraction samples was quan-
ified by real-time PCR based on the protocol described by
ewhurst-Maridor et al. (2004). Samples to be quantified were
iluted 1/64 in diethyl pyrocarbonate (DEPC) treated distilled
ater containing carrier RNA. Reverse transcription was car-
ied out in a 24-well plate (Applied Biosystems, Warrington,
K) in 30l volumes containing 10l of RNA, 5 mM MgCl2,
× reverse transcription buffer, 1 mM dNTPs, 2.75M of RSV
F primer (Dewhurst-Maridor et al., 2004), 30 units RNasin
ibonuclease inhibitor, 5 units AMV-RT and DEPC-treated dis-
illed water. Synthesis of cDNA was carried out in a PTC-200
hermocycler (MJ Research Inc., USA) at 42 ◦C for 30 min and
9 ◦C for 5 min. Real-time PCR was carried out in a 48-well
ptical PCR plate (Applied Biosystems, Warrington, UK) in
0l volumes containing 6l of cDNA, 1× TaqMan Univer-
al PCR Master Mix, 200 nM of RSV probe A, 600 nM of each
SV AF and RSV AR primers (Dewhurst-Maridor et al., 2004)
nd DEPC-treated distilled water. Real-time PCR was carried
ut in ABI Prism 7000 (Applied Biosystems, Warrington, UK)
sing the following conditions: initial denaturation at 95 ◦C for
0 min, and 45 cycles of 95 ◦C for 15 s, 55 ◦C for 45 s and
0 ◦C for 1 s. The result of amplification was analyzed using
BI-PRISM 7000 SDS software. A standard curve was gener-
ted from three fold dilutions of RNA-extracted from a HeLa
ell culture infected with hRSV strain A2 arbitrarily attributed
06 genome/100l. The hRSV RNA content in test samples
s expressed in arbitrary units derived by comparison with the
tandard curve.
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ecovery rates of hRSV from continuous iodixanol gradients
PEG-precipitated virus Continuous gr
Volumea (ml) PFU/mla (×104) Total PFUa (×104) Density (g ml−
17532 0.8 64 ± 5.66 51.2 ± 4.52 1.15–1.19
5843 0.7 3.23 ± 0.24 2.26 ± 0.16 1.15–1.16
a Mean of two gradients, ±Standard deviation.odixanol gradient. The amount of viral F glycoprotein in gradient fractions
as determined by ELISA. The peak fraction 8 was diluted 1:2 in NT buffer
ontaining MgSO4 and layered on a continuous iodixanol gradient.
. Results
hRSV R17532 and N5843 viruses from clarified, infected
ell lysates were concentrated by PEG precipitation and purified
rom the precipitates by sequential ultracentrifugation on discon-
inuous and continuous iodixanol gradients. After centrifugation
f PEG-concentrated virus through discontinuous iodixanol gra-
ients, a visible opaque band was observed for both virus strains
t the 20–36% interface. In order to confirm the presence of virus
articles in these bands, samples from all fractions of the discon-
inuous gradient of strain R17532 were measured for the amount
f viral F glycoprotein by ELISA. A peak of viral glycoprotein
ontent was found to coincide with fraction 8 which contained
he opaque band (Fig. 1). A second peak of viral antigen was
lso detected in fraction 2 at a density of 1.10 g/ml and may
epresent microsomal membrane containing viral glycoproteins
r cell-associated infectious virus.
Centrifugation of the fraction 8 band of virus on continuous
radients yielded a single opaque band for both virus strains at
imilar positions. In order to examine the distribution of virus
n the gradients, viral infectivity, the amount of viral glycopro-
ein and genomic RNA were analysed by infectious focus assay,
Ab capture ELISA and quantitative RT-PCR, respectively, in
ll fractions samples of virus strain R17532. The distribution
f viral genome was found to be consistent with that of the
glycoprotein across the gradient, and the increase of viral
enome was proportional with the infectivity titres in fractions
–9 (Fig. 2). The coincidence of the F glycoprotein, viral genome
nd infectivity peaks confirmed the presence of virus particles,
adient
1) Volume (ml) PFU/mla (×104) Total PFUa (×104) Recovery (%)
1.5 24.35 ± 17.66 36.52 ± 35.92 71
0.9 1.66 ± 0.93 1.49 ± 0.30 66
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Eig. 2. Purification of hRSV strain R17532 on continuous iodixanol gradient
lycoprotein by ELISA () was determined across the fractions. The infectivit
n the region of density 1.15–1.19 g/ml. Similar results were also
btained with strain N5843 and the density of the peak fraction
f the two virus strains averaged 1.16 ± 0.02 g/ml. The recovery
ate of the virus from fractions containing peak amounts of F
lycoprotein and genomic RNA ranged from 66 to 71%, with
n average of 69% (Table 1).
. Discussion
As hRSV generally has a low infectivity titre after propaga-
ion in cell culture, for purification, large volumes of cell culture
uids are required in order to achieve high virus titres in the
urified product. Here, virus in clarified culture supernatants was
oncentrated by PEG precipitation and resuspended in NT buffer
ontaining 100 mM MgSO4. MgSO4 was incorporated into the
rocedure to stabilize the virus (Fernie and Gerin, 1980). A pre-
iminary comparative study confirmed that the infectivity titre
f virus purified in the presence of MgSO4 was 8-fold higher
han that without MgSO4 (data not shown).
Ultracentrifugation of PEG concentrates through discontinu-
us iodixanol density gradients produced two peaks of material
etected by optical density. Viral F protein peaked at the 20–36%
nterface, with a calculated density of 1.10–1.20 g/cm3, and this
orresponds to the previous 30–45% sucrose interface contain-
ng virus band (Mbiguino and Menezes, 1991; Ueba, 1978).
he second peak at the 45–60% interface (1.20–1.29 g/ml) is
hought to contain host material. A similar optical density peak
as present in the discontinuous gradients of Mbiguino and
enezes who, as here, fractionated virus derived from infected
ell lysates, but was absent from those of Ueba who used only
larified culture superntants to minimise the host cell debri in
he starting material.
On the subsequent continuous gradient, both strains of hRSV
ere banded at 1.15–1.19 g/ml, a different density to that of
RSV banded on sucrose at 1.18–1.20 g/ml. This finding is con-
istent with that of Mbiguino and Menezes (1991) who reported
ariable virus densities with different purification media. The
ield of both virus strains was approximately 70% after the com-
lete purification procedure, which is somewhat higher than the
Fdensity (g/ml, ), amount of hRSV genome by real-time PCR ( ) and F
s (PFU/ml, x) were determined for fractions 5–9 only.
ate reported previously for sucrose gradients (Mbiguino and
enezes, 1991; Ueba, 1978). Consistent with the findings of
hese authors, the infectivity titre was improved by incorporat-
ng EDTA (1 mM) to the fraction samples prior to the infectivity
ssay to disaggregate the virus (data not shown). Unlike sucrose,
odixanol is not toxic to HeLa cells and preliminary experiments
ave shown that it has no effect on the viral titre (data not shown),
llowing the infectivity assays to be carried out directly on the
urified samples without dialysis.
In conclusion, the results of the present study show that
odixanol density gradient centrifugation yields high recovery
f purified infectious hRSV particles. The method is particu-
arly suited to the purification of early passage isolates which
roduce low virus titers after propagation in cell culture.
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